Long-Term Follow-Up of Patients Treated with Infliximab for Ulcerative Colitis: Predictive Factors of Response—An Observational Study
- 26 February 2016
- journal article
- research article
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 61 (7) , 2051-2059
Abstract
Aim To evaluate the early and long-term efficacy of infliximab in ulcerative colitis and to determine predictors of response and colectomy. Methods This is an ambidirectional cohort study in a tertiary referral center including patients who started infliximab within 2005 and 2008 and monitored until 2014. Efficacy was evaluated by partial Mayo scores at weeks 2, 4, 8, 30, and 54. Long-term treatment maintenance with infliximab and colectomy requirements were recorded. Results Fifty-three patients were included with a median follow-up of 69.5 months. Clinical remission at the time point assessments was 40.8, 47.2, 54.7, 54.7, and 49.1 %. At the time of maximal follow-up, the proportion of patients under infliximab maintenance was 24.5 %. A higher level of albumin (OR 1.4, CI 95 % 1.06–1.8; p = 0.017) was predictive of a higher remission rate at week 8. Concomitant immunomodulators beyond 6 months were predictive of infliximab’s long-term maintenance (OR 15.8, CI 95 % 1.8–135.4; p = 0.012). Colectomy was required in 41.5 %. Factors associated with a higher rate of colectomy at week 54 were previous treatment with cyclosporine (OR 3.4, CI 95 % 1.2–9.7; p = 0.012), absence of response at week 8 (OR 10.3, CI 95 % 3.3–31.7; p < 0.001), and not receiving concomitant immunomodulators (OR 4.1, CI 95 % 1.8–9; p = 0.002). Colectomy rates within the first 54 weeks were closely dependent on the number of variables present: none (0 %), 1 (26.3 %), 2 (71.4 %), or 3 (100 %) of them (log rank <0.0001). Conclusions Low albumin, previous treatment with cyclosporine, absence of a concomitant immunomodulator, and lack of response at week 8 negatively affected the efficacy of infliximab in ulcerative colitis.Keywords
This publication has 22 references indexed in Scilit:
- Long-term Combination Therapy with Infliximab Plus Azathioprine Predicts Sustained Steroid-free Clinical Benefit in Steroid-dependent Ulcerative ColitisInflammatory Bowel Diseases, 2014
- Combination Therapy With Infliximab and Azathioprine Is Superior to Monotherapy With Either Agent in Ulcerative ColitisGastroenterology, 2014
- Comparison of efficacy, pharmacokinetics, and immunogenicity between infliximab mono‐ versus combination therapy in ulcerative colitisJournal of Gastroenterology and Hepatology, 2014
- Severe Disease Activity and Cytomegalovirus Colitis Are Predictive of a Nonresponse to Infliximab in Patients with Ulcerative ColitisDigestive Diseases and Sciences, 2013
- Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trialThe Lancet, 2012
- Serum albumin concentration: a predictive factor of infliximab pharmacokinetics and clinical response in patients with ulcerative colitisInt. Journal of Clinical Pharmacology and Therapeutics, 2010
- Long-term outcome after infliximab for refractory ulcerative colitisJournal of Crohn's and Colitis, 2008
- Changes in Clinical Characteristics, Course, and Prognosis of Inflammatory Bowel Disease during the Last 5 Decades: A Population-Based Study from Copenhagen, DenmarkInflammatory Bowel Diseases, 2007
- Response to Corticosteroids in Severe Ulcerative Colitis: A Systematic Review of the Literature and a Meta-RegressionClinical Gastroenterology and Hepatology, 2007
- Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitisGastroenterology, 2004